Truist analyst David MacDonald raised the firm’s price target on Encompass Health (EHC) to $140 from $135 and keeps a Buy rating on the shares after meeting with management. The firm believes Encompass is seeing “robust” fundamentals due to strong demand trends and its scale. Ongoing labor improvement, increased artificial intelligence investment and the company’s development activity further support a bullish stance on shares, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health to build 50-bed inpatient rehabilitation hospital in Texas
- Encompass Health: Strong Financial Performance and Growth Potential Drive Buy Rating
- Encompass Health price target raised to $140 from $130 at UBS
- Encompass Health Reports Strong Q2 2025 Results
- Encompass Health Reports Strong Q2 Earnings Growth